CareDx to Divest Lab Products for $170M, Reports Strong 39% Q1 Revenue Growth
CDNA sits 67% above its 52-week low of $10.96.
Summary
CareDx announced a definitive agreement to divest its Lab Products business to EuroBio Scientific for $170 million in cash, a significant strategic move. Concurrently, the company released strong preliminary first-quarter 2026 financial results, reporting total revenue growth of approximately 39% year-over-year to $118 million. This divestiture, representing a material portion of CareDx's market capitalization, provides substantial financial flexibility for future strategic investments or potential capital returns to shareholders. The transaction is designed to sharpen the company's focus on its higher-growth Precision Medicine Testing Services and Patient and Digital Solutions segments, which demonstrated robust performance with 48% and 33% revenue growth, respectively, in Q1. These strong preliminary results, coupled with the strategic divestiture, position CareDx for a more streamlined and focused growth trajectory. Investors will closely watch the completion of the divestiture by the end of Q3 2026 and the company's subsequent capital allocation decisions, with further guidance anticipated during the Q1 earnings call on April 28, 2026.
At the time of this announcement, CDNA was trading at $18.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $899.9M. The 52-week trading range was $10.96 to $21.49. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.